Alpha 2.0
Login Register
» Authors » Daniela Sorriento

Daniela Sorriento

Explore the profile of Daniela Sorriento including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 79
Citations 1984
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Molecular Biology
Pharmacology
Top 10 Co-Authors
Guido Iaccarino
Bruno Trimarco
Gaetano Santulli
Michele Ciccarelli
Jessica Gambardella
Antonella Fiordelisi
Pietro Campiglia
Ersilia Cipolletta
Maddalena Illario
Carmine Del Giudice
Published In
Int J Mol Sci
Front Cardiovasc Med
Oxid Med Cell Longev
Vascul Pharmacol
Hypertension
Affiliations
Soon will be listed here.
Recent Articles
1.
L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy
Fiordelisi A, Cerasuolo F, Avvisato R, Buonaiuto A, Maisto M, Bianco A, et al.
Cardiovasc Diabetol . 2024 Dec; 23(1):450. PMID: 39707340
In patients with type II diabetes, the development of diabetic cardiomyopathy (DC) is associated with a high risk of mortality. Left ventricular hypertrophy, diastolic dysfunction, and exercise intolerance are the...
2.
Oxidative Stress and Inflammation in Cancer
Sorriento D
Antioxidants (Basel) . 2024 Nov; 13(11). PMID: 39594545
Reactive oxygen species (ROS) are important signaling molecules, physiologically synthesized by oxygen metabolism [...].
3.
Macrophages participate in doxorubicin-induced cardiac damage
Cerasuolo F, Gambardella J, Santulli G, Fiordelisi A, Wang X, Prevete N, et al.
Vascul Pharmacol . 2024 Jul; 155:107309. PMID: 38985612
No abstract available.
4.
L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy
Fiordelisi A, Gambardella J, Cerasuolo F, Viti A, Avvisato R, Buonaiuto A, et al.
Vascul Pharmacol . 2024 Jul; 155:107316. PMID: 38985610
No abstract available.
5.
Macrophages release miRNAs in response to Doxorubicin with a potential role in indirect cardiac damage
Buonaiuto A, Gambardella J, Santulli G, Fiordelisi A, Wang X, Prevete N, et al.
Vascul Pharmacol . 2024 Jul; 155:107302. PMID: 38985604
No abstract available.
6.
Early impairment in mitochondrial quality check and function precedes the development of cardiac phenotypes in an mouse model of Fabry Disease
Gambardella J, Fiordelisi A, Cerasuolo F, Buonaiuto A, Avvisato R, Viti A, et al.
Vascul Pharmacol . 2024 Jul; 155:107320. PMID: 38985588
No abstract available.
7.
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease
De Marco O, Gambardella J, Bianco A, Fiordelisi A, Cerasuolo F, Buonaiuto A, et al.
Front Cardiovasc Med . 2024 May; 11:1396996. PMID: 38756750
Fabry disease (FD), also known as Anderson-Fabry disease, is a hereditary disorder of glycosphingolipid metabolism, caused by a deficiency of the lysosomal alpha-galactosidase A enzyme. This causes a progressive accumulation...
8.
Endothelial Extracellular Vesicles Enriched in microRNA-34a Predict New-Onset Diabetes in Coronavirus Disease 2019 (COVID-19) Patients: Novel Insights for Long COVID Metabolic Sequelae
Mone P, Jankauskas S, Manzi M, Gambardella J, Coppola A, Kansakar U, et al.
J Pharmacol Exp Ther . 2024 Feb; 389(1):34-39. PMID: 38336381
Emerging evidence indicates that the relationship between coronavirus disease 2019 (COVID-19) and diabetes is 2-fold: 1) it is known that the presence of diabetes and other metabolic alterations poses a...
9.
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations
Gambardella J, Riccio E, Bianco A, Fiordelisi A, Cerasuolo F, Buonaiuto A, et al.
Front Cardiovasc Med . 2024 Feb; 11:1341590. PMID: 38327490
Fabry disease (FD) is a lysosomal storage disorder due to the impaired activity of the -galactosidase A (GLA) enzyme which induces Gb3 deposition and multiorgan dysfunction. Exercise intolerance and fatigue...
10.
Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
Mone P, Guerra G, Lombardi A, Illario M, Pansini A, Marro A, et al.
Pharmacol Res . 2024 Jan; 200:107055. PMID: 38176528
No abstract available.